|
Hydroxychloroquine with or without azithromycin
|
Cavalcanti et al. [8]
|
Did not improve clinical status at 15 days for mild-to-moderate COVID-19
|
Open-label RCT
|
|
Remdesivir
|
Beigel et al. [11]
|
Shorten the time to recovery for hospitalized patients
|
Double-blind RCT
|
|
Wang et al. [14]
|
Was not associated with time to clinical improvement
|
Double-blind RCT
|
|
Ribavirin
|
Tong et al. [15]
|
Was not associated with improved negative conversion time/improved mortality rate for severe patients
|
Retrospective study
|
|
Lopinavir–ritonavir (LPV/r)
|
Cao et al. [16]
|
Did not significantly accelerate clinical improvement for severe patients
|
Open-label RCT
|
|
Interferon beta-1b + lopinavir–ritonavir + ribavirin
|
Hung et al. [17]
|
Alleviating symptoms and shortening the duration of viral shedding and hospital stay in patients with mild to moderate COVID-19
|
Open-label RCT
|
|
Arbidol vs. lopinavir–ritonavir
|
Zhu et al. [18]
|
Arbidol monotherapy may be superior to lopinavir/ritonavir for viral clearance
|
Retrospective study
|
|
Arbidol + lopinavir–ritonavir vs. lopinavir–ritonavir
|
Deng et al. [19]
|
Arbidol and LPV/r combination may be superior to LPV/r alone in elevating negative conversion rate
|
Retrospective study
|
|
Arbidol and moxifloxacin
|
Yu et al. [20]
|
Reducing viral load and inflammation
|
Retrospective study
|
|
Empirical antiviral regimens with or without arbidol
|
Xu et al. [21]
|
Arbidol could accelerate and enhance the process of viral clearance
|
Retrospective study
|
|
Tocilizumab
|
Eimer et al. [24]
|
Did not reduce all-cause mortality but was associated with a shorter time on mechanical ventilation
|
Retrospective study
|
|
Dexamethasone
|
RECOVERY Collaborative group [25]
|
Lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone but not among those receiving no respiratory support
|
Open-label RCT
|
